| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Donovan, Jenny L.
University of Bristol
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (8/8 displayed)
- 2017Developing outcome measures assessing wound management and patient experiencecitations
- 2017Prostate Specific Antigen (PSA) testing of men in UK general practice:citations
- 2017Alcohol consumption and prostate cancer incidence and progressioncitations
- 201610-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.citations
- 2016Validating the use of hospital episode statistics data and comparison of costing methodologies for economic evaluationcitations
- 2011Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English citiescitations
- 2010Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy resultcitations
- 2008Prostate-cancer mortality in the USA and UK in 1975 - 2004: an ecological studycitations
Places of action
| Organizations | Location | People |
|---|
article
Validating the use of hospital episode statistics data and comparison of costing methodologies for economic evaluation
Abstract
<p><strong>Objectives</strong> To evaluate the accuracy of routine data for costing inpatient resource use in a large clinical trial and to investigatecosting methodologies.</p><p><strong>Design</strong> Final-year inpatient cost profiles were derived using (1) data extracted from medical records mapped to the National HealthService (NHS) reference costs via service codes and (2) Hospital Episode Statistics (HES) data using NHS reference costs.Trust finance departments were consulted to obtain costs for comparison purposes.</p><p><strong>Setting</strong> 7 UK secondary care centres.</p><p><strong>Population</strong> A subsample of 292 men identified as having died at least a year after being diagnosed with prostate cancer in Cluster randomisedtriAl of PSA testing for Prostate cancer (CAP), a long-running trial to evaluate the effectiveness and cost-effectivenessof prostate-specific antigen (PSA) testing.</p><p><strong>Results</strong> Both inpatient cost profiles showed a rise in costs in the months leading up to death, and were broadly similar. The differencein mean inpatient costs was £899, with HES data yielding ∼8% lower costs than medical record data (differences compatiblewith chance, p=0.3). Events were missing from both data sets. 11 men (3.8%) had events identified in HES that were all missingfrom medical record review, while 7 men (2.4%) had events identified in medical record review that were all missing from HES.The response from finance departments to requests for cost data was poor: only 3 of 7 departments returned adequate data setswithin 6 months.</p><p><strong>Conclusions</strong> Using HES routine data coupled with NHS reference costs resulted in mean annual inpatient costs that were very similar tothose derived via medical record review; therefore, routinely available data can be used as the primary method of costingresource use in large clinical trials. Neither HES nor medical record review represent gold standards of data collection.Requesting cost data from finance departments is impractical for large clinical trials.</p><p><strong>Trial registration number</strong> ISRCTN92187251; Pre-results.</p>